Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-977-0 | CAS number: 101-80-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- February 1962
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Remarks:
- Non GLP. The report does not detail a specific method; however it documents dose levels and responses in detail, so is deemed appropriate for use in the support of a formal registration. Sufficient dose ranges and numbers are detailed; hence it is appropriate for use based on reliability and animal welfare grounds.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 962
- Report date:
- 1962
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- 4,4’-Oxydianiline was administered as a suspension in peanut oil in single doses to male rats (1/dose level) via intragastric intubation at doses of 40, 60, 90, 200, 300, 450, 670, 1000, 1500, 2250, 3400, or 5000 mg/kg. Survivors were killed 9-13 days later and were examined for pathologic changes. In addition, 3 animals were dosed at levels of 1500, 3400, and 5000 mg/kg and killed, when moribund, for pathologic evaluation.
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- 4,4'-oxydianiline
- EC Number:
- 202-977-0
- EC Name:
- 4,4'-oxydianiline
- Cas Number:
- 101-80-4
- Molecular formula:
- C12H12N2O
- IUPAC Name:
- 4,4'-oxydianiline
- Test material form:
- not specified
- Details on test material:
- - Name of test material (as cited in study report): 4,4'-Oxydianiline
- Haskell lot/batch No.: 2675 (other codes: MPD-2706)
- Molecular formula (if other than submission substance): Not specified
- Molecular weight (if other than submission substance): Not specified
- Smiles notation (if other than submission substance): Not specified
- InChl (if other than submission substance): Not specified
- Structural formula attached as image file (if other than submission substance): Not specified.
- Substance type: Not specified
- Physical state: Not specified
- Analytical purity: Not specified
- Impurities (identity and concentrations): Not specified
- Composition of test material, percentage of components: Not specified
- Isomers composition: Not specified
- Purity test date: Not specified
- Expiration date of the lot/batch: Not specified
- Radiochemical purity (if radiolabelling): Not applicable
- Specific activity (if radiolabelling): Not applicable
- Locations of the label (if radiolabelling): Not applicable
- Expiration date of radiochemical substance (if radiolabelling): Not applicable
- Stability under test conditions: Not applicable
- Storage condition of test material: Not applicable
- Other: Not applicable
Constituent 1
- Specific details on test material used for the study:
- 4,4'-oxydianiline
4,4'-diaminodiphenyl ether
CAS 101-80-4
Test animals
- Species:
- rat
- Strain:
- other: Charles River - CD
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Not specified
- Age at study initiation: Not specified
- Weight at study initiation: Not specified
- Fasting period before study: Not specified
- Housing:Not specified
- Diet (e.g. ad libitum): Not specified
- Water (e.g. ad libitum): Not specified
- Acclimation period: Not specified
ENVIRONMENTAL CONDITIONS
- Temperature (°C): Not specified
- Humidity (%): Not specified
- Air changes (per hr): Not specified
- Photoperiod (hrs dark / hrs light): Not specified
IN-LIFE DATES: Not specified
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- peanut oil
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: Not specified.
- Amount of vehicle (if gavage): Not specified
- Justification for choice of vehicle: Not specified
- Lot/batch no. (if required): Not specified
- Purity: Not specified
MAXIMUM DOSE VOLUME APPLIED: 5000 mg/kg
DOSAGE PREPARATION (if unusual): Not specified - Doses:
- 5000, 3400, 2250, 1500, 1000, 670, 450, 300, 200, 90, 60, 40 mg/kg
Additional 3 animals were dosed at 5000, 3400, 2250 for sacrificial purposes. - No. of animals per sex per dose:
- 1
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: Survivors were sacrificed 9 to 13 days following administration
- Frequency of observations and weighing: Not specified
- Necropsy of survivors performed: No.
- Other examinations performed: clinical signs, body weight,, histopathology, blood observations - Statistics:
- Not specified.
Results and discussion
Effect levels
- Key result
- Sex:
- male
- Dose descriptor:
- approximate LD50
- Effect level:
- > 1 000 - < 1 500 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: At 1500 mg/kg and above: mortality = 1/1 At 1000 mg/kg and below: mortality = 0/1
- Mortality:
- Mortality was 0/1, 0/1,0/1, 0/1, 0/1, 0/1, 0/1, 0/1, 1/1, 1/1, 1/1, 1/1 at 40, 60, 90, 200, 300, 450, 670, 1000, 1500, 2250, 3400, and 5000 mg/kg, respectively.
- Clinical signs:
- Clinical signs of toxicity included discomfort (=200 mg/kg), inactivity (=670 mg/kg), glassy and pale eyes (=670 mg/kg), prostration (=2250 mg/kg), slow shallow respiration (=2250 mg/kg), salivation (3400 mg/kg), lacrimation (=2250 mg/kg), tremors (1500 mg/kg), convulsive movements of the head (5000 mg/kg), incoordination (1500 mg/kg), hair loss (200, 300, 450, 670, 1000, and 1500 mg/kg), bulging eyes (3400 and 5000 mg/kg), and ruffled fur (670 and 1000 mg/kg). In addition, weight loss was observed at 60, 200, 300, 450, 670, 1000, 1500, 3400, and 5000 mg/kg.
- Body weight:
- Test subjects at 1500 mg/kg dose levels and below were documented as suffering from weight loss. No specific information or observational timepoints were noted within the report.
- Gross pathology:
- Pathological changes at lethal doses included congestion of viscera in the one animal (2500 mg/kg); all others could not be observed due to advanced post-mortem changes. In the animals that were dosed, and killed when moribund, pathological changes included slightly brown blood and/or tissues (1500 and 5000 mg/kg), stomach distended with food (=3400 mg/kg), liver injury (1500 mg/kg), and spleen and adrenal gland congestion (1500 mg/kg). Pathological changes at non-lethal doses included liver injury (200 and 1000 mg/kg), kidney injury (1000 mg/kg), and extramedullary blood formation (=200 mg/kg). A single dose of 90 mg/kg caused no detectable injury.
- Other findings:
- - Organ weights: Not specified.
- Histopathology: Not specified.
- Potential target organs: Not specified.
- Other observations: Not specified.
Any other information on results incl. tables
The following tabulated data is presented within the report:
Peanut oil suspension, % |
Dosage mg/kg |
Mortality |
Clinical Signs |
Pathological changes |
25 |
5000 |
1/1 |
Discomfort, inactivity, glassy and pale eyes, died within 3 days
|
Not observed due to advanced postmortem change
|
25 |
3400 |
1/1 |
Discomfort, inactivity, glassy and pale eyes, prostration, salivation, slow shallow respiration, died within 2 days |
Not observed due to advanced postmortem change
|
20 |
2250 |
1/1 |
Discomfort, lacrimation, Increased water intake, inactivity, glassy and pale eyes, prostration, shallow respiration, died in 2 days
|
Congestion of viscera
|
20 |
1500 |
1/1 |
Discomfort, inactivity, glassy and pale eyes, ruffled fur, hair loss, incoordination, tremors, weight loss, died within 12 day*
|
Not observed due to advanced postmortem change
|
20 |
1000 |
0/1 |
Discomfort, inactivity, pale and glassy eyes, ruffled fur, hair loss, weight loss for 9 days
|
Liver and kidney injury, extra-medullary blood formation
|
20 |
670 |
0/1 |
Discomfort, inactivity, pale and glassy eyes, ruffled fur, hair loss, weight loss for 5 days
|
Extramedullary blood formation
|
10 |
450 |
0/1 |
Discomfort, hair loss, weight loss for 3 days
|
Extramedullary blood formation
|
10 |
300 |
0/1 |
Discomfort, hair loss, weight loss for 3 days
|
Extramedullary blood formation
|
10 |
200 |
0/1 |
Discomfort, hair loss, weight loss for 3 days
|
Extramedullary blood formation
|
5 |
90 |
0/1 |
None |
None |
1 |
60 |
0/1 |
Weight loss 2 days |
None |
1 |
40 |
0/1 |
None |
None |
Animals Sacrificed for Pathology |
||||
Peanut oil suspension, % |
Dosage mg/kg |
Mortality |
Clinical Signs |
Pathological changes |
25 |
5000 |
1/1 |
Discomfort, inactivity, lacrimation, bulging eyes, shallow respiration, prostration, convulsive movements of head, weight loss, killed 4 days after dosing |
Blood slightly brown, stomach distended with food
|
25 |
3400 |
1/1 |
Discomfort, inactivity, lacrimation, bulging eyes, shallow respiration, prostration, weight loss, killed 1 day after dosing
|
Stomach distended with food
|
20 |
1500 |
1/1 |
Discomfort, Inactivity, glassy and pale eyes, hair loss, weight loss, killed 7 days after dosing
|
Liver injury spleen and adrenal gland congested, blood and tissues slightly brown
|
Applicant's summary and conclusion
- Interpretation of results:
- Category 3 based on GHS criteria
- Remarks:
- Toxic
- Conclusions:
- Although direct correlation between the approximate lethal dose (ALD) and the median lethal dose (or LD50) cannot be specified exactly, based on the results of the study it is deemed appropriate to consider the substance as "harmful" by oral ingestion.
However this result differs from the Harmonized European Classification detailed in Annex VI of the CLP regulation. According to this regulation, the substance must be considered as "Toxic" and classified H301 category 3. - Executive summary:
On the basis of the results from a study conducted on rats, and according to the CLP regulation criteria, the substance can be considered "harmful" by oral ingestion.
However this result differs from the Harmonized European Classification detailed in Annex VI of the CLP regulation. According to this regulation, the substance must be considered as "Toxic" and classified H301 category 3.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.